Stockscreener 앱 받기
50.54
0.48%
0.24
시장 영업 전:
50.54
Tg Therapeutics Inc 주식(TGTX)의 최신 뉴스
TG Therapeutics Stock On Fire: Up 25% With 6-Day Winning Streak - Trefis
Director Sagar Lonial receives 8,325 stock tracking units at TG Therapeutics (TGTX) - Stock Titan
TG Therapeutics (TGTX) director awarded 8,325 Stock Tracking Units in Form 4 filing - Stock Titan
[Form 4] TG THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
TG Therapeutics (NASDAQ: TGTX) director awarded 8,325 stock tracking units - Stock Titan
Director at TG Therapeutics (TGTX) granted 8,325 stock tracking units - Stock Titan
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with Promising Revenue Growth and Analyst Confidence - DirectorsTalk Interviews
TG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trial - MSN
TG Therapeutics (TGTX) soars 7.5%: Is further upside left in the stock? - MSN
TGTX stock up on positive phase I data for subcutaneous Briumvi - MSN
Why is TG Therapeutics (TGTX) down 5.7% since last earnings report? - MSN
5-Day Rally Sends TG Therapeutics Stock Up 23% - Trefis
TG Therapeutics Stock Rockets 23% With 5-Day Winning Streak - Trefis
TG Therapeutics Shareholders Reject Executive Compensation at Meeting - TipRanks
Shareholders at TG Therapeutics (NASDAQ: TGTX) reject 2026 executive pay - Stock Titan
TGTX rises on positive phase I data for subcutaneous Briumvi in MG - MSN
TG THERAPEUTICS INC (TGTX) Stock Chart - ChartMill
TGTX Stock Quote Price and Forecast - CNN
TG Therapeutics (TGTX) Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released - Sahm
TGTX: Directors and auditors were approved, but executive compensation was not - TradingView
TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen - MSN
TG Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock? - Yahoo Finance
TG Therapeutics stock hits 52-week high at 44.7 USD By Investing.com - Investing.com Australia
TGTX Climbs on Upbeat Subcutaneous BRIUMVI Data and Expanded Development Plans - Moomoo
TGTX climbs on upbeat subcutaneous BRIUMVI data and expanded development plans - Quiver Quantitative
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
TGTX Stock Jumps As Briumvi Pipeline Momentum Accelerates - timothysykes.com
TGTX Stock Surges As Briumvi Data Fuel Growth Story - StocksToTrade
Why TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS Treatment - Yahoo Finance
TG Therapeutics Stock Is Surging Today: What's Driving The Action? - Benzinga
TG Therapeutics stock hits 52-week high at 44.7 USD - Investing.com
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG - Yahoo Finance
TG Therapeutics rises on early-stage trial data for Briumvi injectable - MSN
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
TGTX stock jumps 5% on positive early data for at-home BRIUMVI in muscle disease - MSN
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease - Stocktwits
TG Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
TG Therapeutics initiates phase 2 trial of BRIUMVI for MG By Investing.com - Investing.com Australia
TG Therapeutics rallies on positive subcutaneous BRIUMVI data for MG - grafa.com
Why Is TG Therapeutics Stock Gaining Tuesday? - Benzinga
TG Therapeutics (TGTX) Launches Mid-Stage Trial for Briumvi in M - GuruFocus
TG Therapeutics (TGTX) Unveils Positive Phase 1 Data for Briumvi in Myasthenia Gravis - GuruFocus
TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial - Moomoo
TG Therapeutics initiates phase 2 trial of BRIUMVI for MG - Investing.com UK
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial - The Manila Times
82% of myasthenia gravis patients improved in early BRIUMVI shot test - Stock Titan
A Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial Updates - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 19.52% Upside Potential in Biotechnology - DirectorsTalk Interviews
1.27%
1.43%
자본화:
|
볼륨(24시간):